ligustroflavone and Brain-Ischemia

To investigate the anticerebral ischemic properties of YGY-E (apigenin-7-O-β-D-glucopyranosy l-4'-O-α-L-rhamnopy-ranosid, a flavonoid glycoside extracted from plant phoenix-tail fern), focusing on its effects on neuronal apoptosis.. In vitro YGY-E treatment was examined in primary cultured rat hippocampal neurons subjected to hypoxia-reoxygenation (H-R) injury. In addition, in vivo effects of YGY-E on neuronal apoptosis were measured by Hoechst staining and in situ DNA end labeling (TUNEL). Finally, B cell lymphoma/lewkmia-2 (Bcl-2) level in ischemic rat brain tissue was evaluated with immunohistochemistry and western blot analyses.. In vitro YGY-E (50-100 μg/mL) treatment increased the survival rate compared to that of the vehicle-treated group (P < 0.05 and P < 0.01, respectively). In in vivo experiments, YGY-E (2.5-10 mg/kg) decreased the percentage of apoptotic neurons (P < 0.01), increased Bcl-2 (P < 0.01) in ischemic rat brain tissue. These effects were dose dependent.. Our findings indicate that YGY-E's neuroprotective effects may be because of its inhibition of neuronal apoptosis by increasing Bcl-2 expression.

Topics: Animals; Animals, Newborn; Apigenin; Apoptosis; Brain; Brain Ischemia; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glycosides; Hippocampus; Hypoxia; In Situ Nick-End Labeling; Male; Neurons; Neuroprotective Agents; Oxygen; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Rats, Wistar